Does Combination Therapy With SGLT2 Inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?

Frontiers in Cardiovascular Medicine

Ze-Lin Zhan¹  Li-Min Zhao²  Mei Qiu³  Miao Zhang⁴ 

[1] Class 3, Clinical Medicine, Grade 2019, The Second Clinical Medical College, Southern Medical University, Guangzhou, China;Department of Endocrinology, Shenzhen Longhua District Central Hospital, Shenzhen, China;Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China;Department of Nephrology, Shenzhen Hospital of Beijing University of Chinese Medicine, Shenzhen, China;

关键词: SGLT2 inhibitors;    RAS blockers;    type 2 diabetes mellitus;    cardiorenal events;    Heart failure;   

DOI  :  10.3389/fcvm.2021.679124

来源: Frontiers

【 授权许可】

CC BY